Adamis Pharmaceuticals Corporation

0.4248-0.0025-0.59%Vol 394.10K1Y Perf -44.48%
May 18th, 2022 16:00 DELAYED
BID0.4206 ASK0.4420
Open0.4262 Previous Close0.4273
Pre-Market- After-Market0.44
 - -  0.02 4.05%
Target Price
1.25 
Analyst Rating
Hold 3.00
Potential %
194.26 
Finscreener Ranking
★+ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.12
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     41.72
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.67 
Earnings Rating
Buy
Market Cap63.61M 
Earnings Date
16th May 2022
Alpha-0.01 Standard Deviation0.32
Beta1.29 

Today's Price Range

0.41740.4419

52W Range

0.31181.48

5 Year PE Ratio Range

-2.30-2.70

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Sell
Performance
1 Week
25.01%
1 Month
-7.11%
3 Months
-29.20%
6 Months
-52.78%
1 Year
-44.48%
3 Years
-77.51%
5 Years
-88.61%
10 Years
-95.74%

TickerPriceChg.Chg.%
ADMP0.4248-0.0025-0.59
AAPL140.82-8.4200-5.64
GOOG2 248.02-86.0100-3.69
MSFT254.08-12.1200-4.55
XOM90.65-1.4600-1.59
WFC42.11-1.6000-3.66
JNJ175.50-3.3200-1.86
FB192.24-10.3800-5.12
GE75.20-1.2000-1.57
JPM120.09-2.0900-1.71
Financial StrengthValueIndustryS&P 500US Markets
2.60
3.10
0.01
0.03
-5 202.70
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-211.10
-1 566.20
-1 501.20
-236.20
-
RevenueValueIndustryS&P 500US Markets
-1 899 850.00
-0.01
-23.10
0.12
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.03-0.07-133.33
Q03 2021-0.06-0.0350.00
Q04 2020--0.16-
Q03 2020-0.04-0.10-150.00
Q02 2020-0.07-0.13-85.71
Q01 2020-0.05-0.10-100.00
Q04 2019--0.08-
Q03 2019-0.06-0.11-83.33
Earnings Per EndEstimateRevision %Trend
3/2022 QR-0.030.00-
6/2022 QR-0.040.00-
12/2022 FY-0.1318.75Positive
12/2023 FY-0.0544.44Positive
Next Report Date-
Estimated EPS Next Report-0.03
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume394.10K
Shares Outstanding149.73K
Shares Float148.53M
Trades Count987
Dollar Volume170.16K
Avg. Volume853.05K
Avg. Weekly Volume981.82K
Avg. Monthly Volume744.58K
Avg. Quarterly Volume832.76K

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) stock closed at 0.4273 per share at the end of the most recent trading day (a -8.03% change compared to the prior day closing price) with a volume of 947.71K shares and market capitalization of 63.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 171 people. Adamis Pharmaceuticals Corporation CEO is Dennis J. Carlo.

The one-year performance of Adamis Pharmaceuticals Corporation stock is -44.48%, while year-to-date (YTD) performance is -29.37%. ADMP stock has a five-year performance of -88.61%. Its 52-week range is between 0.3118 and 1.48, which gives ADMP stock a 52-week price range ratio of 9.67%

Adamis Pharmaceuticals Corporation currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 2.23, a price-to-sale (PS) ratio of -36.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -136.73%, a ROC of -248.16% and a ROE of -314.55%. The company’s profit margin is -%, its EBITDA margin is -1 501.20%, and its revenue ttm is $-1 899 850.00 , which makes it $-0.01 revenue per share.

Of the last four earnings reports from Adamis Pharmaceuticals Corporation, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. Adamis Pharmaceuticals Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adamis Pharmaceuticals Corporation is Hold (3), with a target price of $1.25, which is +194.26% compared to the current price. The earnings rating for Adamis Pharmaceuticals Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamis Pharmaceuticals Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamis Pharmaceuticals Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.91, ATR14 : 0.05, CCI20 : -44.57, Chaikin Money Flow : 0.01, MACD : -0.03, Money Flow Index : 36.56, ROC : 8.87, RSI : 47.64, STOCH (14,3) : 61.40, STOCH RSI : 0.79, UO : 59.32, Williams %R : -38.60), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamis Pharmaceuticals Corporation in the last 12-months were: David C. Benedicto (Sold 3 603 shares of value $2 208 ), David J. Marguglio (Sold 11 859 shares of value $7 117 ), Dennis J. Carlo (Sold 10 490 shares of value $6 287 ), Ronald B. Moss (Sold 8 199 shares of value $4 949 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company. It is focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy, and opioid overdose. Its SYMJEPI (epinephrine) Injection products are used in the emergency treatment of acute allergic reactions, including anaphylaxis.

CEO: Dennis J. Carlo

Telephone: +1 858 997-2400

Address: 11682 El Camino Real, San Diego 92130, CA, US

Number of employees: 171

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

85%15%

Bearish Bullish

62%38%

Bearish Bullish

66%34%

News

Stocktwits